Dermatology for Practice, 2018, issue 2

Editorial

Jak se v medicíně připravujeme na svět 4.0?

prof. MUDr. Vladimír Mihál, CSc.

Dermatol. praxi. 2018;12(2):55  

Review articles

Erythroderma

doc. MUDr. Ivana Kuklová, CSc.

Dermatol. praxi. 2018;12(2):60-63 | DOI: 10.36290/der.2018.010  

Erythroderma also sometimes called exfoliative dermatitis, is a severe and potentially life-threatening condition that presentswith diffuse erythema and scaling involving most of the skin surface area (≥90 percent, in the most common definition). Erythrodermais a rare condition. The annual incidence has been estimated to be approximately 1 per 100,000 in the adult population.The most common cause of erythroderma is the exacerbation of a preexisting inflammatory dermatosis, most often psoriasis oratopic dermatitis. A hypersensitivity drug reaction is the second most frequent cause of erythroderma (approximately 20 percentof cases) followed by...

Maintenance Therapy in Atopic Dermatitis

MUDr. Zuzana Plzáková, Ph.D.

Dermatol. praxi. 2018;12(2):64-68 | DOI: 10.36290/der.2018.011  

Atopic dermatitis is a chronic inflammatory disease with increasing incidence and multifactorial pathogenesis, including skin barrierdysfunction. Emolients and moisturizers improving skin barrier function are important milestones in therapy of atopic dermatitis.

Local therapy – conventional acne treatment

MUDr. Silvia Kubovčíková

Dermatol. praxi. 2018;12(2):70-72 | DOI: 10.36290/der.2018.012  

The article presents a comprehensive overview of local anti-acne products and their use in acne treatment.

Interdisciplinary overviews

Fabry disease

MUDr. Gabriela Dostálová, MUDr. Petra Reková, MUDr. Klára Sedláková, PhD., MUDr. Ondřej Kodet, MUDr. Alena Slováková, MUDr. Kristýna Bayerová, MUDr. Lenka Roblová, MUDr. Lubor Goláň, prof. MUDr. Aleš Linhart, DrSc.

Dermatol. praxi. 2018;12(2):80-82  

Fabry disease is an X-linked lysosomal storage disease. Enzyme replacement therapy (ERT) is available in our country since 2004.The sooner diagnosis is made, the better ERT stabilizes the progression of Fabry disease. The timing of ERT is important in orderto prevent irreversible organ damage.

Photoprotection during antibiotic and antineoplastic treatment

MUDr. Jiří Ettler, MUDr. PharmDr. Jan Dvořák, MUDr. Filip Prusík, doc. MUDr. Karel Ettler, CSc.

Dermatol. praxi. 2018;12(2):84-86  

One of the possible adverse effect in various drugs is increased sensitivity to sun irradiation. It can manifest as a phototoxic orphotoallergic reaction. Patients using high‑risk medication should be educated about photoprotection. Measures of sun protectioninclude avoidance of exposure to the sun during midday, wearing photoprotective clothes and aplication of sunscreens.

Case report

Pityriasis rubra pilaris after gastroenteritis

MUDr. Tereza Marušiaková

Dermatol. praxi. 2018;12(2):73-77 | DOI: 10.36290/der.2018.013  

Pityriasis rubra pilaris is an uncommon chronic papulosquamous skin disease with unknown etiology. The typical symptoms arefolicular associated papules spreading into pink scaly plaques and palmoplantar keratoderma. Diagnosis is done according tothe typical clinical signs in correlation with a histopathological examination. The treatment can be problematic, oral retinoids areused most common. The case report describes pacient with pityriasis rubra pilaris, which occured after bowel infection.

Cosmetic dermatology spot

New methods to improve skin quality

MUDr. Kateřina Klauzová

Dermatol. praxi. 2018;12(2):92-96  

The term rejuvenation is used in a narrow sense, only for processes that affect the production and remodeling of collagen, increasthe production of elastic fibers and other proteins, which is clinically manifested as wrinkle reduction, skin tone increase, and tissueshrinkage., Rejuvenating procedures in a broader sense, include those that return to the younger appearance of the area. There arecurrently many technologies and procedures that affect individual signs of aging, such as various surgical procedures, lipotransferaugmentation, fillers, lasers, radiofrequency, chemical peeling, ultrasound, absorbable or non-absorbable fibers and others.

At a glance

Criteria for treatment of onychomycosis

doc. MUDr. Magdalena Skořepová, CSc.

Dermatol. praxi. 2018;12(2):78-79  

The article presents a brief review of criteria for grading the severity of onychomycosis and the ensuing therapeutic recommendations.

Pharmacological profile

Apremilast in dermatology

MUDr. Dana Prusíková

Dermatol. praxi. 2018;12(2):87-91 | DOI: 10.36290/der.2018.016  

Current system therapy represents in some cases a compromise between the safety and efficacy of treatment, the route of administration(injection x oral form) and the need for laboratory monitoring during treatment. In particular, the safety of treatmentis an important factor in patients with psoriasis in selecting a particular treatment due to the presence of frequent comorbiditiessuch as diabetes mellitus or cardiovascular disease. Apremilast as a selective PDE4 inhibitor increases cAMP levels and acts specificallyon intracellular signaling, gene and protein expression. It reduces the inflammatory response by reducing the expressionof proinflammatory...

Orbis Pictus Medicus

Morbus Darier

prof. MUDr. Zdeněk Doležel, CSc., MUDr. Blanka Pinková, MUDr. Hana Bučková, Ph.D., MUDr. Pavlína Autratová

Dermatol. praxi. 2018;12(2):97-98  


Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.